Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -£47,265 | -£157,490 | -£45,976 | £19,880 |
| Dep. & Amort. | £22,427 | £28,710 | £26,359 | £12,456 |
| Deferred Tax | £0 | £0 | £0 | £994 |
| Stock-Based Comp. | £0 | £3,516 | £6,471 | £3,981 |
| Change in WC | -£34,383 | £17,457 | £4,912 | -£12,909 |
| Other Non-Cash | £8,593 | £79,290 | -£4,381 | £1,053 |
| Operating Cash Flow | -£50,628 | -£28,517 | -£12,615 | £25,455 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -£7,496 | -£9,832 | -£16,296 | -£9,461 |
| Net Acquisitions | £9,004 | £0 | -£99,206 | £0 |
| Inv. Purchases | £0 | £0 | £0 | £0 |
| Inv. Sales/Matur. | £0 | £0 | £0 | £0 |
| Other Inv. Act. | £4,124 | £12,638 | £59,040 | £0 |
| Investing Cash Flow | £5,632 | £2,806 | -£56,462 | -£9,461 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -£466 | -£3,117 | £33,442 | -£4,520 |
| Stock Issued | £17,526 | £651 | £80,154 | £51,600 |
| Stock Repurch. | £0 | £0 | £0 | £0 |
| Dividends Paid | £0 | £0 | £0 | £0 |
| Other Fin. Act. | -£14,152 | -£10,237 | -£14,974 | -£873 |
| Financing Cash Flow | £2,908 | -£12,703 | £98,622 | £46,207 |
| Forex Effect | -£940 | £845 | £2,796 | £0 |
| Net Chg. in Cash | -£43,066 | -£37,569 | £32,341 | £62,201 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | £103,716 | £141,285 | £108,944 | £46,743 |
| End Cash | £60,650 | £103,716 | £141,285 | £108,944 |
| Free Cash Flow | -£58,124 | -£38,349 | -£28,911 | £15,994 |